Alkylating agents
Radiation + Chemotherapy for Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Boulder, Colorado
This trial is testing different radiation therapy regimens to see which is more effective in treating patients with limited-stage small cell lung cancer when given together with chemotherapy.
Alkylating agents
Melphalan + Prednisone + Thalidomide/Lenalidomide for Multiple Myeloma
Recruiting2 awardsPhase 3
Fort Collins, Colorado
This trial compares melphalan/prednisone with thalidomide to melphalan/prednisone with lenalidomide to see which is more effective in treating newly diagnosed multiple myeloma.
Hormone Therapy
Hormone Therapy + Immunotherapy for Advanced Breast Cancer
Recruiting2 awardsPhase 3
Fort Collins, Colorado
This trial is testing tamoxifen citrate or letrozole with or without bevacizumab to treat stage IIIB or IV breast cancer. Estrogen fuels breast cancer cell growth, so hormone therapy with tamoxifen or letrozole can block estrogen and stop tumor growth. Bevacizumab is an immunotherapy that may help the body's immune system fight the cancer. Researchers want to see if it is more effective with or without bevacizumab.
Popular Filters
Phase 3 Trials
Alkylating agents
Chemotherapy +/− Bevacizumab for Breast Cancer
Recruiting1 awardPhase 3
Fort Collins, Colorado
This trial is testing doxorubicin hydrochloride, cyclophosphamide, and paclitaxel with or without bevacizumab to see how well they work in treating patients with lymph node-positive or high-risk, lymph node-negative breast cancer.
Alkylating agents
Chemotherapy +/− Bevacizumab for Stage II Colon Cancer
Recruiting2 awardsPhase 3
Glenwood Springs, Colorado
This trial is testing a combination of drugs to treat patients who have had surgery for stage II colon cancer, to see if it is more effective than a standard combination of drugs.
Trials With No Placebo
Alkylating agents
Chemotherapy +/− Bevacizumab for Stage II Colon Cancer
Recruiting2 awardsPhase 3
Glenwood Springs, Colorado
This trial is testing a combination of drugs to treat patients who have had surgery for stage II colon cancer, to see if it is more effective than a standard combination of drugs.
Tyrosine Kinase Inhibitor
Imatinib or Dasatinib for Chronic Myeloid Leukemia
Recruiting1 awardPhase 2
Fort Collins, Colorado
This trial looks at two different doses of imatinib mesylate and dasatinib to see how well they work in treating patients with previously untreated chronic phase chronic myelogenous leukemia.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.